IDSA GUIDELINES Bundle (free trial)

MRSA

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/53996

Contents of this Issue

Navigation

Page 17 of 17

Strength of Recommendation and Evidence Quality Strength A B C Definition Quality I II III Good evidence for or against a recommendation. Moderate evidence for or against a recommendation. Poor evidence to support a recommendation. Definition Evidence from ≥ 1 randomized, controlled trial. Evidence from ≥ 1 clinical trial, without randomization, from cohort or case-controlled analytic studies (preferably from > 1 center), from multiple time-series, or dramatic results from uncontrolled experiments. Opinions of respected authorities, based on experience, descriptive studies, or reports of expert committees. Abbreviations ABSSSI, acute bacterial skin and skin structure infections; CA-MRSA, community- associated MRSA; CLSI, Clinical and Laboratory Standards Institute; HA-MRSA, healthcare-associated MRSA; I & D, incision and drainage; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin- sensitive S. aureus; SSTI, skin and soſt tissue infection; TMP-SMX, trimethoprim/ sulfamethoxazole; VISA, vancomycin-intermediate S. aureus Source Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-e55. [PMID: 21208910] Disclaimer This Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. MRS081132 5740 Executive Drive Suite 218 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2011 All rights reserved.

Articles in this issue

Links on this page

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - MRSA